NASDAQ$ALXO
ALX Oncology Holdings Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
ALX Oncology reported a net loss for the second quarter of 2021, made progress in clinical trials, and maintained a strong cash position.
ALX Oncology reported a net loss of $27.5 million for the second quarter of 2021. The company is focused on advancing its clinical programs, particularly ALX148, and reported positive data updates. ALX Oncology ended the quarter with a strong cash balance of $328.1 million.
- Reported a net loss of $27.5 million for the second quarter of 2021.
- Made significant progress in advancing ALX148 clinical programs.
- Presented positive data updates from clinical trials.
- Maintained a strong cash position of $328.1 million as of June 30, 2021.
Headline financials
Revenue & EPS history
ALX Oncology · Revenue · Quarterly
$527K
Forward guidance
ALX Oncology did not provide specific financial guidance for the remainder of 2021. The company's focus remains on advancing its clinical programs and providing updates on its progress.
Tailwinds
- Continued advancement of ALX148 clinical trials across multiple indications.
- Potential for ALX148 to address unmet needs in cancer treatment.
- Strong financial position to support ongoing research and development activities.
- Positive data updates from clinical trials.
- Strategic collaborations to expand the development and commercialization of ALX148.
Headwinds
- Dependence on the success of ALX148 and other pipeline candidates.
- Risk associated with clinical trial outcomes and regulatory approvals.
- Potential competition from other companies developing cancer therapies.
- Uncertainties related to the COVID-19 pandemic and its impact on clinical trials and operations.
- Need for additional financing to support long-term growth and development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.7%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+26.0%
Q4 2024
Best reaction
-21.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -10.2% | -6.8% | -13.2% | |
| Q3 2025 | +15.5% | +8.5% | +20.3% | |
| Q2 2025 | +7.4% | +57.9% | +72.4% | |
| Q1 2025 | -8.2% | -0.2% | +25.9% | |
| Q4 2024 | +26.0% | -6.4% | -50.4% | |
| Q3 2024 | -5.2% | -12.4% | +5.9% | |
| Q1 2024 | -2.4% | -8.7% | -45.8% | |
| Q4 2023 | +3.0% | -16.2% | -17.2% | |
| Q3 2023 | +13.2% | +21.8% | +70.5% | |
| Q2 2023 | +1.4% | -2.6% | -1.4% | |
| Q1 2023 | +0.6% | -7.0% | +23.3% | |
| Q4 2022 | -13.6% | -15.9% | -28.7% | |
| Q3 2022 | -1.8% | +1.1% | -14.2% | |
| Q2 2022 | +2.6% | +26.6% | +5.6% | |
| Q1 2022 | -6.8% | -8.1% | -24.1% | |
| Q4 2021 | +7.7% | -1.3% | +2.7% | |
| Q3 2021 | +8.8% | +6.3% | -26.4% | |
| Q2 2021 | +0.6% | +2.1% | +16.6% | |
| Q1 2021 | -1.1% | -1.6% | +7.3% | |
| Q4 2020 | -21.9% | -19.4% | -24.8% | |
| Q3 2020 | +4.2% | +34.6% | +65.1% | |
| Q2 2020 | +2.0% | -3.8% | -10.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro